Scholarlink

Objective <p>To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex<sup>®</sup>) injection (SDI).</p> Methods <p>A retrospective case series of 4 patients (6 eyes).</p> Results <p>In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (<i>n</i> = 1), and granulomatosis with polyangiitis (GPA) (<i>n</i> = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (<i>n</i> = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.</p> Conclusion <p>SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月6日

查看全文
  • Battuya Ganbold,
  • Ba Trung Nguyen,
  • Jia-Horung Hung,
  • Azadeh Mobasserian,
  • Zheng Xian Thng,
  • Hashem Ghoraba,
  • Negin Yavari,
  • Dalia El Feky,
  • Cigdem Yasar,
  • Aim-On Saengsirinavin,
  • Xiaoyan Zhang,
  • Frances Andrea Anover,
  • S. Saeed Mohammadi,
  • Ngoc Tuong,
  • Trong Than,
  • Anadi Khatri,
  • Osama Elaraby,
  • Amir Akhavanrezayat,
  • Ankur Sudhir Gupta,
  • Woong Sun Yoo,
  • Quan Dong Nguyen,
  • Christopher Or

摘要

Objective

To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI).

Methods

A retrospective case series of 4 patients (6 eyes).

Results

In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.

Conclusion

SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.